| Detected | Trial | Change |
|---|---|---|
| 2026-08-13 | NCT06969430 A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in… |
Primary endpoint(s) modified |
| 2026-08-13 | NCT06969430 A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in… |
Enrollment increased: 134 -> 154 participants |
| 2026-07-28 | NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer |
Trial completed |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-11 | NCT07758608 Renal Impairment Pharmacokinetics (PK) Trial of Afabicin | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06930625 | A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly… | Acromegaly | Recruiting |
| NCT06129539 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric… | Central Precocious Puberty | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With… | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Recruiting |
| NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in… | Acute Myeloid Leukemia | Recruiting |
| Phase 1 | |||
| NCT04855656 | Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With… | Advanced Solid Tumor | Recruiting |
| NCT07035769 | A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single… | Healthy Participants | Recruiting |
| NCT07758608 | Renal Impairment Pharmacokinetics (PK) Trial of Afabicin | Renal Impairment | Not Yet Recruiting |